Background and Purpose-Thrombolysis improves outcome of patients with acute ischemic stroke, but it is unknown whether thrombolysis has a measurable effect on long-term outcome in a defined population. Methods-We prospectively assessed demographic data, management, and outcome of acute ischemic stroke patients admitted within 48 hours to 18 primary care hospitals of the canton of Bern (969 299 inhabitants) during 12 months. Blinded follow-up was obtained at 3 and 12 months. Predictors of mortality and favorable outcome (modified Rankin Scale score Յ2) at 3 and 12 months using logistic regression were analyzed. Results-From December 2007 to December 2008, 807 patients (mean age, 72 years) were included. Median National
R
andomized trials and observational studies have shown that thrombolysis improves 3-month outcome in patients with acute ischemic stroke (AIS). [1] [2] [3] Some case series and randomized controlled trials reported sustained effects of thrombolysis at long-term follow-up (FU). 4 -7 However, it remains unknown whether thrombolysis has a measurable effect on stroke outcome not only in clinical trials patients but also on a population level in daily clinical practice.
The aim of the present study was to assess whether thrombolysis improves 3-month outcome in a defined population and whether the beneficial effect persists at 1 year. We therefore prospectively assessed patients with AIS admitted to acute care hospitals of the canton of Bern, Switzerland, during a 12-month period.
Materials and Methods

Study Area and Population
The study was conducted in the geographically well-defined area of the canton of Bern (online-only Appendix 1; http://stroke.ahajournals.org). On December 31, 2007, 962 982 people (50.8% women; 17.1% 65 years or older) were living in the canton. There are both rural and urban districts. General practitioners are serving the population, but stroke patients are usually referred to hospital.
The Hospitals
The "Inselspital" is the main teaching hospital of the University of Bern. There are 18 nonuniversity hospitals that participated in this study (Tiefenauspital, Zieglerspital, Lindenhofspital, Langenthal, Sonnenhofspital, Salemspital, St Imier, Biel, Aarberg, Burgdorf, Langnau, Münsingen, Belp, Thun, Riggisberg, Interlaken, Frutigen, Zweisimmen, Saanen). Additional smaller hospitals that treated Ͻ10 stroke patients in 2006 were not invited to participate. For thrombolysis, acute stroke patients are referred to the "Inselspital," which provides comprehensive stroke management with all specialists as needed. Only 1 hospital apart from the Inselspital performed a small number of thrombolyses.
Study Population
Patients with first-ever or recurrent AIS admitted within 48 hours after symptom onset to 1 of the hospitals between December 3, 2007 and December 2, 2008, were included in this study. Stroke was defined as "rapidly developing clinical symptoms and/or signs of focal, and at times global loss of cerebral function, with symptoms lasting Ͼ24 hours or leading to death, with no apparent cause other than that of vascular origin." 8 Patients with transient episodes lasting Ͻ24 hours, silent infarcts, intracranial hemorrhage, and sinus venous thrombosis were excluded. Foreign patients with stroke in Switzerland were excluded. If patients or their relatives refused to give written consent, then they were not allowed to be contacted for FU examination. The ethics committee of the canton of Bern approved the study.
Patient Assessment
Patients were assessed immediately after admission. Clinical and demographic data were obtained from patients, their relatives, general practitioners, and hospital records. Preexisting comorbid conditions were summarized in the Charlson Comorbidity Index. 9 Events were classified as first-ever or recurrent. Stroke severity was assessed with the National Institutes of Health Stroke Scale (NIHSS) score. 10 For multivariate regression analysis, NIHSS was categorized into tertiles: NIHSS 0 to 3, NIHSS 4 to 9, and NIHSS Ն10. Patients underwent CT or MR scans, carotid ultrasound, electrocardiography, and echocardiography (transthoracic or transoesophageal) and longterm electrocardiography to determine stroke etiology. The following stroke risk factors were assessed as defined previously: sex; hypertension; diabetes; cigarette smoking; hypercholesterolemia; coronary heart disease; previous transient ischemic attack or stroke; and family history of transient ischemic attack and stroke. 4 Stroke subtype was classified according to TOAST criteria. 11 Intravenous thrombolysis within 4.5 hours, intra-arterial thrombolysis within 6 hours, and mechanical thrombectomy within 8 hours were performed according to international and institutional guidelines (http://neurologie. insel.ch/fileadmin/neurologie/neurologie_users/Pdf/StrokeRichtlinien-22-10-09.pdf). 12, 13 Antithrombotic and secondary preventive therapy were administered as recommended by European guidelines. 14,15
Data Collection
Demographic and clinical characteristics were collected prospectively using standardized questionnaires. Data collection was monitored by a contract organization (www.vereinoutcome.ch). Outcome was assessed 90 days (Ϯ14 days) and 12 months (Ϯ14 days) after hospital admission by telephone interview. Trained study nurses (clinical trial unit, University of Bern) blinded for baseline characteristics and management performed the interviews. If patients were unable to communicate, then caregivers were contacted. Functional outcome was scored with the modified Rankin Scale. 16 
Primary and Secondary Outcomes
Primary outcome was case fatality and favorable clinical outcome (modified Rankin Scale score 0 -2) at 3 and 12 months. Secondary outcome was in-hospital mortality and length of hospital stay. We further assessed variation of primary and secondary outcomes with respect to age, gender, severity of stroke on admission, stroke risk factors, comorbidities, and thrombolysis.
Statistical Analysis
Baseline characteristics are described using frequencies for categorical and mean and standard deviation or median and range for continuous information. Differences between thrombolysed and nonthrombolysed patients were assessed using 2 test (for comparison of frequencies across categories) and Kruskal-Wallis test (for comparison of continuous variables). Multivariable linear regression was used to analyze length of hospital stay and factors by which mean length of stay varied. We report regression coefficients with 95% CI. For the binary outcomes mortality and handicap, we estimated risk ratios using multivariable Poisson regression 17 with inverse probability of censoring weights (IPCW). 18 The rationale to use IPCW was to account for the fact that likelihood of having obtained follow-up information was not the same for all patients leaving the hospital. For example, patients of older age and with higher NIHSS scores were less likely to have follow-up information. However, older age and higher NIHSS score are risk factors for higher mortality (online-only Appendix 5 gives a simplified argument for using IPCW). IPCW were derived from a logistic regression with availability of follow-up information as the outcome including all predictors also included in mortality analyses. Separate IPCW were calculated for 3-month and 12-month outcomes, and patients who died in hospital had their IPCW set to 1. Results of Poisson regression models were expressed as risk ratios with 95% CI. PϽ0.05 was considered statistically significant. All analyses were performed using Stata version 12 (StataCorp).
Results
Eight hundred seven stroke patients qualified for our study ( Figure) . Patient characteristics, vascular risk factors, stroke etiology, and management are given in Table 1 , including differences between thrombolysed and nonthrombolysed patients. Thrombolysis was performed mainly in the university hospital in Bern (nϭ103), overall in 107 of 807 patients (13%). Thirty-five patients (33%) underwent intravenous thrombolysis, 41 (48%) underwent intra-arterial thrombolysis, and 5 (5%) underwent mechanical thrombectomy. One patient underwent intravenous thrombolysis and intra-arterial thrombolysis, and 25 (23%) patients had a combination of mechanical thrombectomy with either intravenous thrombolysis or intra-arterial thrombolysis. In-hospital mortality, length of hospital stay, mortality, and clinical outcome at 3 and 12 months are shown in Table 2 . Age 75 years and older and NIHSS score Ն4 were independently associated with a longer hospital stay, whereas in-hospital death and thrombolysis shortened length of hospital stay (online-only Appendix 2). However, thrombolysis did not shorten length of hospital stay by increasing in-hospital mortality. The interaction P value was 0.67 when including an interaction term between in-hospital death and thrombolysis in the multivariate regression of length of stay. Age 85 years and older and NIHSS score Ն10 were independent predictors of in-hospital mortality (onlineonly Appendix 3).
Eighty-one percent of patients consented to be contacted for FU. Patients giving consent tended to be younger (Pϭ0.0972), less severely affected (NIHSS score Ͻ12; Pϭ0.0832), were less likely smokers (Pϭ0.0493), and were less likely to have hyperlipidemia (Pϭ0.0342); 481 patients (83.6%) who consented for FU assessment could be contacted at 3 months, and 433 (75.3%) could be contacted at 12 months ( Figure) . Detailed information on outcome of thrombolysed and nonthrombolysed patients is shown in Table 2 and online-only Appendix 4. Estimated cumulative mortality at 3 months was 20.6% and at 12 months 27.4%. Age older than 75 years, higher NIHSS score, and comorbid conditions were independent predictors of mortality at 3 and 12 months, whereas hyperlipidemia was an additional predictor of mortality at 12 months (Table 3) ; 48.2% (95% CI, 44.1-52.3%) of patients had an estimated favorable outcome at 3 months and 44.6% (95% CI, 40.4 -48.8%) at 12 months. Thrombolysis was the only modifiable independent predictor of favor- 
Discussion
In this hospital-based prospective study with blinded FU, we assessed short-term and long-term outcome in patients with AIS in the canton of Bern; 13% of stroke patients admitted within 48 hours were thrombolysed. Thrombolysis exerted a measurable effect on 3-month outcome in this population and was sustained at 12 months. Randomized controlled studies have shown the beneficial effect of thrombolysis. The SITS-MOST registry and a Canadian registry confirmed safety and efficacy of thrombolysis in daily clinical practice. 3, 19 However, whether thrombolysis will have a measurable impact on stroke outcome in a population has not been investigated. A simulation model indicated that thrombolysis would benefit patients but would not have any impact on the general prognosis of stroke in a population. 20 Our study shows, however, probably for the first time, that thrombolysis exerts a measurable effect on stroke outcome not only in clinical trial patients but also in a well-defined population in daily clinical practice. This effect was measurable at 3 months and sustained at 12 months. In univariate comparison, thrombolysed patients contacted at 12 months tended to be more often independent (Pϭ0.07) and alive than nonthrombolysed patients, even though stroke severity in thrombolysed patients was significantly higher than in nonthrombolysed patients. Both groups also differed in other characteristics; therefore, multivariable analysis was necessary to assess the impact of baseline characteristics and treatment on outcome. Lack of significance in univariate analysis is also related to the small sample size. In multivariable analysis, thrombolysis was a significant predictor of favorable outcome at 3 and 12 months. Similar to results observed in randomized controlled trials, mortality was not influenced by thrombolysis. 21 Despite more than a decade of knowledge about the effectiveness of stroke thrombolysis, many AIS patients are still not thrombolysed because of a lack of rapid access to centers that provide this treatment. Hospital-based series have shown that thrombolysis rates in AIS patients vary between 5.7% and 21.7% 22 but can be increased by prehospital triage to 23.7%. 23 However, rates of thrombolysis among all AIS patients within a general nonurban population remain Յ3%. 19, 24 Even though the 13% thrombolysis rate in our study was higher than in previous reports, only one-fourth of 
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all patients presenting within 6 hours were thrombolysed, and there is still much work to do to enhance thrombolysis rates within our study population. The reason for higher thrombolysis rates in our study is partly attributable to the fact that patients were not only treated with intravenous but also treated with endovascular thrombolysis. In endovascular therapy, the time window for treatment is longer and selected patients were treated Ͼ6 hours after symptom onset. Male gender was a further predictor of handicap beside stroke severity, age, and Charlson Comorbidity Index. More men experienced a stroke than did women. Gender differences in stroke incidence and outcome have been reported previously; a systematic review on gender differences in stroke showed a 33% higher incidence in men, but with higher fatality rates in women. 25 Women with first-ever stroke are older than men, more severely disabled, and have different risk factors and stroke subtypes. 26 The reason why more women remain handicapped after a stroke is poorly understood. Women may have a poorer functional status before the ictus and less social support, because they are more likely widowed.
Population-based studies on outcome in stroke patients in Switzerland are scarce. Only 1 population-based study in Switzerland assessed incidence but not outcome of first-ever ischemic stroke in the city of Basle. 27 Some information on stroke outcome in Switzerland was provided from 1631 patients randomized in the International Stroke Trial. 28 Six months after stroke, 23.1% of patients were dead, 43.8% were dependent, and only 33.1% were independent. However, the International Stroke Trial was performed in the 1990s, before the advent of thrombolysis. Therefore, our hospital-based study in a large area provides probably the most accurate information on stroke outcome in Switzerland.
Our study has limitations. First, it was hospital-based and we missed stroke patients who were not admitted or who were admitted after 48 hours. However, given the population of nearly 1 million, we did not have the means to perform a population-based study, as would have been considered "ideal." 29 Second, smaller hospitals treating Ͻ10 stroke patients per year were not included, and in participating hospitals some admitted patients might have been missed to be included, although there were study coordinators in each participating hospital. Third, our ethical committee required written informed consent to contact patients for blinded FU, but 19% of patients did not agree to be contacted. Fourth, 16% of patients at 3 months and 21% at 12 months who agreed for FU were lost. However, informative loss of patients was accounted for by using inverse probability of censoring weights for all follow-up analyses. Last, because thrombolysis was performed mainly in 1 single center with a small sample size, this may potentially affect the interpretation of our results.
Conclusions
Thirteen percent of AIS patients admitted within 48 hours to Bernese hospitals underwent thrombolysis, which exerted a measurable effect on outcome in this population. This effect was measurable at 3 months and was sustained at 12 months. Age, stroke severity, Charlson Comorbidity Index, and male gender were independent nonmodifiable predictors of outcome. 
